Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ.

J Clin Oncol. 2015 Nov 20;33(33):3911-20. doi: 10.1200/JCO.2014.59.1503. Epub 2015 Aug 17.

PMID:
26282654
2.

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.

Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA.

Haematologica. 2017 Sep;102(9):1617-1625. doi: 10.3324/haematol.2017.163766. Epub 2017 May 26.

3.

Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing.

Ryland GL, Jones K, Chin M, Markham J, Aydogan E, Kankanige Y, Caruso M, Guinto J, Dickinson M, Prince HM, Yong K, Blombery P.

J Clin Pathol. 2018 Oct;71(10):895-899. doi: 10.1136/jclinpath-2018-205195. Epub 2018 May 14.

PMID:
29760015
4.

Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.

Kim SJ, Shin HT, Lee HO, Kim NK, Yun JW, Hwang JH, Kim K, Park WY.

Oncotarget. 2016 Oct 18;7(42):68350-68359. doi: 10.18632/oncotarget.12029.

5.

Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M; Multiple Myeloma Research Consortium, Getz G, Golub TR.

Cancer Cell. 2014 Jan 13;25(1):91-101. doi: 10.1016/j.ccr.2013.12.015.

6.

A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.

Bolli N, Li Y, Sathiaseelan V, Raine K, Jones D, Ganly P, Cocito F, Bignell G, Chapman MA, Sperling AS, Anderson KC, Avet-Loiseau H, Minvielle S, Campbell PJ, Munshi NC.

Blood Cancer J. 2016 Sep 2;6(9):e467. doi: 10.1038/bcj.2016.72.

7.

A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.

Jiménez C, Jara-Acevedo M, Corchete LA, Castillo D, Ordóñez GR, Sarasquete ME, Puig N, Martínez-López J, Prieto-Conde MI, García-Álvarez M, Chillón MC, Balanzategui A, Alcoceba M, Oriol A, Rosiñol L, Palomera L, Teruel AI, Lahuerta JJ, Bladé J, Mateos MV, Orfão A, San Miguel JF, González M, Gutiérrez NC, García-Sanz R.

J Mol Diagn. 2017 Jan;19(1):99-106. doi: 10.1016/j.jmoldx.2016.08.004. Epub 2016 Nov 15.

PMID:
27863261
8.

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JM, McLaren S, O' Meara S, Butler AP, Teague JW, Mudie L, Anderson E, Rashid N, Tai YT, Shammas MA, Sperling AS, Fulciniti M, Richardson PG, Parmigiani G, Magrangeas F, Minvielle S, Moreau P, Attal M, Facon T, Futreal PA, Anderson KC, Campbell PJ, Munshi NC.

Nat Commun. 2014;5:2997. doi: 10.1038/ncomms3997.

9.

The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma.

Weißbach S, Langer C, Puppe B, Nedeva T, Bach E, Kull M, Bargou R, Einsele H, Rosenwald A, Knop S, Leich E.

Br J Haematol. 2015 Apr;169(1):57-70. doi: 10.1111/bjh.13256. Epub 2014 Dec 17.

PMID:
25521164
10.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E.

Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.

PMID:
26184520
11.

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M.

Blood. 2014 Jan 30;123(5):632-9. doi: 10.1182/blood-2013-05-504340. Epub 2013 Dec 11.

12.

Multiple Myeloma Genomics: A Systematic Review.

Weaver CJ, Tariman JD.

Semin Oncol Nurs. 2017 Aug;33(3):237-253. doi: 10.1016/j.soncn.2017.05.001. Epub 2017 Jul 18. Review.

PMID:
28729121
13.

Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing.

Lee PJ, Yoo NS, Hagemann IS, Pfeifer JD, Cottrell CE, Abel HJ, Duncavage EJ.

Exp Mol Pathol. 2017 Feb;102(1):156-161. doi: 10.1016/j.yexmp.2017.01.012. Epub 2017 Jan 14.

PMID:
28093192
14.

Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.

Suda T, Hama T, Kondo S, Yuza Y, Yoshikawa M, Urashima M, Kato T, Moriyama H.

BMC Cancer. 2012 Sep 20;12:416. doi: 10.1186/1471-2407-12-416.

15.

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.

Kortuem KM, Braggio E, Bruins L, Barrio S, Shi CS, Zhu YX, Tibes R, Viswanatha D, Votruba P, Ahmann G, Fonseca R, Jedlowski P, Schlam I, Kumar S, Bergsagel PL, Stewart AK.

Blood Cancer J. 2016 Feb 26;6:e397. doi: 10.1038/bcj.2016.1.

16.

Identification of actionable mutations in malignant pleural mesothelioma.

Shukuya T, Serizawa M, Watanabe M, Akamatsu H, Abe M, Imai H, Tokito T, Ono A, Taira T, Kenmotsu H, Naito T, Murakami H, Takahashi T, Endo M, Ohde Y, Nakajima T, Yamamoto N, Koh Y.

Lung Cancer. 2014 Oct;86(1):35-40. doi: 10.1016/j.lungcan.2014.08.004. Epub 2014 Aug 18.

PMID:
25174276
17.

[Cytogenetic abnormalities in high-risk multiple myeloma].

Ishida T.

Nihon Rinsho. 2015 Jan;73(1):28-32. Japanese.

PMID:
25626299
18.

Monitoring multiple myeloma by quantification of recurrent mutations in serum.

Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A.

Haematologica. 2017 Jul;102(7):1266-1272. doi: 10.3324/haematol.2016.160564. Epub 2017 Apr 6.

19.

Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).

Kortüm KM, Langer C, Monge J, Bruins L, Zhu YX, Shi CX, Jedlowski P, Egan JB, Ojha J, Bullinger L, Kull M, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E.

Ann Hematol. 2015 Jul;94(7):1205-11. doi: 10.1007/s00277-015-2344-9. Epub 2015 Mar 7.

20.

Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer.

Shanmugam V, Ramanathan RK, Lavender NA, Sinari S, Chadha M, Liang WS, Kurdoglu A, Izatt T, Christoforides A, Benson H, Phillips L, Baker A, Murray C, Hostetter G, Von Hoff DD, Craig DW, Carpten JD.

BMC Med Genomics. 2014 Jun 18;7:36. doi: 10.1186/1755-8794-7-36.

Supplemental Content

Support Center